Nitrase Therapeutics Inc. has unveiled a protein named glyoxalase domain-containing protein 4 (GLOD4) responsible for catalyzing selective protein nitration. This reflects a new class of enzymatic activity discovered by the company that had not been previously characterized.

Iqure Pharma Inc. has received institutional review board (IRB) approval for a first-in-human study of iQ-007 in healthy volunteers. This follows recent formal approval from the Human Research Ethics Committee (HREC) in Australia for the phase I study, which is expected to begin next month.

Trimtech Therapeutics closed a £25 million (US$31 million) oversubscribed seed funding round to advance its targeted protein degradation treatments for neurodegenerative and inflammatory diseases.

Trimtech Therapeutics closed a £25 million (US$31 million) oversubscribed seed funding round to advance its targeted protein degradation treatments for neurodegenerative and inflammatory diseases.

Onward Medical NV’s spinal cord stimulation system Arc-IM is being investigated to explore its potential to help people with Parkinson's disease.

Mair Therapeutics BV has launched with pre-seed funding from Torrey Pines Investment and Oost NL and with a focus on developing treatments for neurodegenerative disorders, particularly Parkinson’s disease.

Loss of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein (α-Syn) aggregates are the major hallmarks of Parkinson’s disease (PD).

Newronika SpA's AlphaDBS recently secured an investigational device exemption from the U.S. FDA allowing it to begin a pivotal trial to evaluate the safety and efficacy of its adaptive deep brain stimulation system in patients with movement disorders, including Parkinson's disease.